Legend Biotech (LEGN) Profit After Tax (2019 - 2026)
Legend Biotech's (LEGN) quarterly Profit After Tax came in at -$54.3 million in Q1 2026, up 46.24% YoY from -$37.1 million in Q1 2025, and down 275.73% on a QoQ basis from $30.9 million in Q4 2025.
Legend Biotech (LEGN) Profit After Tax (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Profit After Tax data on file, last reported at -$54.3 million in Q1 2026.
- Quarterly Profit After Tax rose 46.24% year-over-year to -$54.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$188.5 million (up 13.59% YoY) and the FY2025 annual result came in at $296.8 million, up 267.68% from the prior year.
- Profit After Tax retreated to -$54.3 million in Q1 2026, from $30.9 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $30.9 million in Q4 2025 to a low of -$199.1 million in Q2 2023.
- A 5-year average of -$74.9 million and a median of -$62.2 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 32288.91% — and 2024, when it soared 18329.78%.
- Tracing LEGN's Profit After Tax over 5 years: stood at -$135.9 million in 2022, then surged by 99.89% to -$144818.0 in 2023, then soared by 18329.78% to $26.4 million in 2024, then increased by 17.05% to $30.9 million in 2025, then plunged by 275.73% to -$54.3 million in 2026.
- The last three Profit After Tax figures came in at -$54.3 million (Q1 2026), $30.9 million (Q4 2025), and -$39.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 33.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.20 Mn |
| Mar 31, 2026 | -54.30 Mn |
| Dec 31, 2025 | 30.90 Mn |
| Sep 30, 2025 | -39.69 Mn |
| Jun 30, 2025 | -125.38 Mn |
| Mar 31, 2025 | -101.00 Mn |
| Dec 31, 2024 | 26.40 Mn |
| Sep 30, 2024 | -125.32 Mn |
| Jun 30, 2024 | -18.20 Mn |
| Mar 31, 2024 | -47.99 Mn |
| Dec 31, 2023 | -144,818.00 |
| Sep 30, 2023 | -62.21 Mn |
| Jun 30, 2023 | -199.13 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -135.88 Mn |
| Sep 30, 2022 | -84.96 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -84.72 Mn |
| Sep 30, 2021 | -124.75 Mn |